Peritoneal carcinomatosis from non-gynecologic malignancies

Prognostic Factors in Patients with Synchronous Peritoneal Carcinomatosis (PC) Caused by a Primary Cancer of the Colon

“…Chu et al 8 and Sadeghi et al 11 reported the outcomes of 100 and 118 cases with PC secondary to non-gynecologic malignancy, respectively. However, only 22 and 69 cases, respectively, had PC secondary to colon cancer at the time of the initial operation.…”

“…The MST after the diagnosis of synchronous PC has been reported to be 4.1 or 7 months. 11,12 The MST in the present series was 6.8 months.…”

“…We classified PC into two categories (limited and extensive) depending on the area of distribution of the PC, regardless of the size of the disseminated nodules, in accordance with the current Japanese guidelines. 19 Sadeghi et al 11 and Jayne et al 12 listed the extent of PC and the T stage of the primary lesion as prognostic factors in patients with colorectal cancer with PC. Chu et al 8 , however, reported that only ascites and lung metastasis affected the prognosis of these patients, casting doubt on the role of PC as a prognostic factor.…”

“…In past reports, the data were often analyzed without distinguishing between synchronous PC and metachronous PC or between colon cancer and rectal cancer. 8,[11][12][13] In regard to the prognosis of colorectal cancer patients with metastasis to the peritoneum, the median survival time (MST) has been reported to be 5-7 months, 11,12 and colorectal cancer with peritoneal metastasis has been considered a terminal condition. The introduction of cytoreductive surgical techniques combined with intraperitoneal chemotherapy has improved the survival of selected patients with PC recently.…”

Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival for Patients with Peritoneal Carcinomatosis from Colorectal Cancer: A Phase II Study from a Chinese Center

“…PC is found in about 8–15% CRC patients at first treatment [1], with a significant negative impacts on both the survival and the quality of life because of refractory ascites, progressive intestinal obstruction and uncontrollable abdominal pain, with approximately 30% of the CRC patients died from this problem [2]. Up to now, the oncology community usually considers CRC PC as a virtually untreatable öterminal condition, for which only palliative measures such ?as systemic chemotherapy, with or without limited surgery and best support care, with limited median overall survival (OS) about 6 months [3]–[5].…”